
    
      Eligible subjects will be randomized to 1 of 2 possible treatment sequences (N=9 per
      sequence) on Study Day 1. Subjects will receive oral 200 mg TR 701 FA or Placebo for TR 701
      FA once daily for 5 days during each treatment period, with a 2 day washout between periods
      (72 hours between doses). On Study Day 5 of each treatment period, subjects will also receive
      oral 60 mg PSE.
    
  